Stockreport

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potent...

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Consistent data across multiple endpoints underscore the potential of PrimeC to redefine the ALS treatment paradigm NeuroSense planning for Phase 3 clinical study in [Read more]